Longeveron

About:

Longeveron is a biotechnology company that focuses on developing cellular therapies for chronic aging-related and life-threatening diseases.

Website: http://longeveron.com

Top Investors: TEDCO, National Institutes of Health, Alzheimer's Association

Description:

Longeveron is a life-sciences company that develops biological solutions for aging and aging-associated diseases. Longeveron's primary investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of healthy adult donors. Lomecel-B™ exhibits various potential mechanisms of action, including pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair effects. These properties make it applicable across a range of diseases. Longeveron is currently conducting clinical trials for Lomecel-B™ in three areas: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

Total Funding Amount:

$34M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Miami, Florida, United States

Founded Date:

2014-01-01

Founders:

Donald Soffer, Joshua M. Hare

Number of Employees:

11-50

Last Funding Date:

2024-07-18

IPO Status:

Public

Industries:

© 2025 bioDAO.ai